Search 

DELSIA is a "venture philanthropy" investment affilate of the research and advocacy foundation Autism Speaks. Our purpose is to transform lives by catalyzing the development and availability of innovative products.

DELSIA is a non-dilutive funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by enabling the translation of scientific breakthroughs and technological advances into products that improve health and quality of life for individuals with ASD and their families. 

Who and what do we invest in? DELSIA partners with for-profit companies to fund development activities necessary for delivering products that address the diverse unmet medical, behavioral health and quality of life needs of the autism community.

DELSIA accepts funding proposals from for-profit entities that include, but are not limited to:

• Entrepreneurs, start-up and small companies

• Life sciences, biotechnology and pharmaceutical companies

• Software, computer and electronic technology companies

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Tania Fernandez is the founder of Dream Catcher Ventures, an advisory firm founded to address the inefficiencies in the marketplace and to align the goals and aspirations of entrepreneurs with investors in the healthcare/biotech sector. It is focused on creating and building disruptive biotech/healthcare companies that are positioned to excel in global markets. The firm also has a strong focus on biotech companies that have assets/technologies that are relevant to the Indian market.

Dr. Fernandez is currently working with BioHealth Innovation on a $50M “Gap Fund” to invest in seed and early stage healthcare/biotech companies primarily in therapeutics, diagnostics, medtech and healthcare IT.

Tania has a doctorate in molecular oncology and a post doctorate in protein chemistry and genetic engineering. She has over fifteen years of experience in the life sciences and 10 years of venture capital investing experience in biotech/ life sciences/healthcare and healthcare delivery.

Easton Capital Investment Group is a venture capital firm based in New York. Easton Capital invests broadly in the life science sector, and considers investment opportunities globally. The firm is likely to make 4-6 allocations in the next 6 months. Allocations typically vary from $250,000 to $5 million, in the form of equity or convertible debt. Allocations are typically made at the venture stage of development, but may be made in seed rounds if a company already has proof of their product's efficacy.

Enso Ventures is a Venture Capital firm that was founded in 2010 and based in London with an additional office in New York. The firm is looking to provide equity capital to high growth companies in the life science space. The firm is currently interested in companies located in Europe, Russia and the US and is looking to make approximately 2-3 investments over the next 6-9 months.

Everett Partners is the venture investing arm of an Akron Ohio based single family office.  The firm owns and manages an incubator in Israel and invests in companies in the life sciences space with a focus on technolog enabled, non-invasive medical devices.

Excel Venture Management is a venture capital firm that was founded in 2008 and is based in Boston, Massachusetts. The firm has managed one fund with committed capital of $125 million, and the firm is currently raising the second fund. Excel Venture Management seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $3 million to $ 5million. The firm plans to invest in 4-5 companies over the next 6-9 months and prefers to invest in companies based in US.